The USPTO issues a Notice of Allowance to BioLineRx (BLRX) for the composition of BL-7010, a novel polymer for the treatment of celiac disease. The patent, when issued, will be valid until at least 2026.
BL-7010 has a high affinity for gliadins, the immunogenic proteins in gluten that cause celiac disease. By sequestering gliadins, BL-7010 masks them from enzyme degradation and prevents the formation of immunogenic peptides that trigger the immune system. It is excreted with gliadin from the digestive tract and not absorbed by the blood.